Ganz Michael B, Saska Brett A
Cleveland Clinic Foundation, Meridia Health System, Department of Medicine, Cleveland, OH 44112, USA.
Congest Heart Fail. 2003 Nov-Dec;Suppl 2:1-4. doi: 10.1111/j.1527-5299.2003.03252.x.
This open-label, drug substitution study was conducted to determine if subjects receiving sustained-release isradipine (SR-I) can be safely switched to sustained-release felodipine (SR-F) and to assess whether SR-I provides better 24-hour blood pressure (BP) control than SR-F. Forty-one men receiving either SR-F 5 mg or SR-F 10 mg once daily for at least 6 months were switched to an equivalent dose of SR-I; BP was measured 2, 4, and 6 weeks after substitution. Significant reductions in systolic BP were seen in the SR-I 10 mg group after 4 weeks and they remained significantly lower through 6 weeks (p< or =0.05). Diastolic BP was reduced, but not significantly. After 6 weeks, SR-F therapy was reinstated, and BP returned toward baseline values. No serious adverse events were reported. SR-I can be safely substituted for SR-F and may provide better 24-hour control of BP than SR-F.
这项开放标签的药物替代研究旨在确定接受缓释伊拉地平（SR-I）的受试者是否可以安全地换用缓释非洛地平（SR-F），并评估SR-I是否比SR-F能更好地控制24小时血压（BP）。41名每天服用一次5毫克或10毫克SR-F至少6个月的男性被换用等量的SR-I；换药后2、4和6周测量血压。4周后，SR-I 10毫克组的收缩压显著降低，至6周时仍显著低于换药前（p≤0.05）。舒张压有所降低，但不显著。6周后，恢复SR-F治疗，血压恢复至基线值。未报告严重不良事件。SR-I可以安全地替代SR-F，并且可能比SR-F能更好地控制24小时血压。
